140 related articles for article (PubMed ID: 19217274)
1. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
Eck MJ; Manley PW
Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
Duveau DY; Hu X; Walsh MJ; Shukla S; Skoumbourdis AP; Boxer MB; Ambudkar SV; Shen M; Thomas CJ
Bioorg Med Chem Lett; 2013 Feb; 23(3):682-6. PubMed ID: 23273517
[TBL] [Abstract][Full Text] [Related]
3. The influence of subclonal resistance mutations on targeted cancer therapy.
Schmitt MW; Loeb LA; Salk JJ
Nat Rev Clin Oncol; 2016 Jun; 13(6):335-47. PubMed ID: 26483300
[TBL] [Abstract][Full Text] [Related]
4. Impact of structural biology and the protein data bank on us fda new drug approvals of low molecular weight antineoplastic agents 2019-2023.
Burley SK; Wu-Wu A; Dutta S; Ganesan S; Zheng SXF
Oncogene; 2024 Jun; ():. PubMed ID: 38886570
[TBL] [Abstract][Full Text] [Related]
5. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.
Manley PW; Stiefl N; Cowan-Jacob SW; Kaufman S; Mestan J; Wartmann M; Wiesmann M; Woodman R; Gallagher N
Bioorg Med Chem; 2010 Oct; 18(19):6977-86. PubMed ID: 20817538
[TBL] [Abstract][Full Text] [Related]
6. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.
Nussinov R; Zhang M; Maloney R; Liu Y; Tsai CJ; Jang H
J Mol Biol; 2022 Sep; 434(17):167569. PubMed ID: 35378118
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
[TBL] [Abstract][Full Text] [Related]
8. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; Zeverijn LJ; van der Velden DL; van de Haar J; Roepman P; de Leng WJ; Jansen AML; van Werkhoven E; van der Noort V; Huitema ADR; Gort EH; de Groot JWB; Kerver ED; de Groot DJ; Erdkamp F; Beerepoot LV; Hendriks MP; Smit EF; van der Graaf WTA; van Herpen CML; Labots M; Hoeben A; Morreau H; Lolkema MP; Cuppen E; Gelderblom H; Verheul HMW; Voest EE
Clin Cancer Res; 2022 Apr; 28(7):1402-1411. PubMed ID: 35046062
[TBL] [Abstract][Full Text] [Related]
9. A novel graph convolutional neural network for predicting interaction sites on protein kinase inhibitors in phosphorylation.
Wang F; Chen YT; Yang JM; Akutsu T
Sci Rep; 2022 Jan; 12(1):229. PubMed ID: 34997142
[TBL] [Abstract][Full Text] [Related]
10. Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.
Lyczek A; Berger BT; Rangwala AM; Paung Y; Tom J; Philipose H; Guo J; Albanese SK; Robers MB; Knapp S; Chodera JD; Seeliger MA
Proc Natl Acad Sci U S A; 2021 Nov; 118(46):. PubMed ID: 34750265
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of targeted and immune based anti-cancer therapies.
Seebacher NA; Stacy AE; Porter GM; Merlot AM
J Exp Clin Cancer Res; 2019 Apr; 38(1):156. PubMed ID: 30975211
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a "drug target prediction-gene microarray analysis-protein network construction" strategy.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
BMC Complement Altern Med; 2019 Mar; 19(1):75. PubMed ID: 30909944
[TBL] [Abstract][Full Text] [Related]
13. Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.
Somlyai G; Collins TQ; Meuillet EJ; Hitendra P; D'Agostino DP; Boros LG
Oncotarget; 2017 Jul; 8(30):50187-50192. PubMed ID: 28418852
[TBL] [Abstract][Full Text] [Related]
14. Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells.
Arvaniti K; Papadioti A; Kinigopoulou M; Theodorou V; Skobridis K; Tsiotis G
Proteomes; 2014 Jul; 2(3):363-381. PubMed ID: 28250386
[TBL] [Abstract][Full Text] [Related]
15. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.
Damaraju VL; Weber D; Kuzma M; Cass CE; Sawyer MB
J Biol Chem; 2016 Sep; 291(36):18809-17. PubMed ID: 27432881
[TBL] [Abstract][Full Text] [Related]
16. Could 5R research help achieve the triple aim?
Ewigman B
Ann Fam Med; 2014; 12(5):399-401. PubMed ID: 25354401
[No Abstract] [Full Text] [Related]
17. Application of MM-GB/SA and WaterMap to SRC Kinase Inhibitor Potency Prediction.
Kohlmann A; Zhu X; Dalgarno D
ACS Med Chem Lett; 2012 Feb; 3(2):94-9. PubMed ID: 24900440
[TBL] [Abstract][Full Text] [Related]
18. DICE: A novel tumor surveillance mechanism-a new therapy for cancer?
Peter ME
Cell Cycle; 2014; 13(9):1373-8. PubMed ID: 24690893
[TBL] [Abstract][Full Text] [Related]
19. Activation pathway of Src kinase reveals intermediate states as targets for drug design.
Shukla D; Meng Y; Roux B; Pande VS
Nat Commun; 2014 Mar; 5():3397. PubMed ID: 24584478
[TBL] [Abstract][Full Text] [Related]
20. Probabilistic Prediction of Protein Phosphorylation Sites Using Classification Relevance Units Machines.
Menor M; Baek K; Poisson G
ACM SIGAPP Appl Comput Rev; 2012 Dec; 12(4):8-20. PubMed ID: 24163645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
